Cambridge-based Gloucester Pharmaceuticals Raises $29 Million in 4th Round

From New England Tech Wire

Cambridge, Mass. -- Gloucester Pharmaceuticals, a
Cambridge-based developer of drugs for cancer treatment, announced on Tuesday
that it has raised $29 million in its fourth round of venture capital, which was
led by Novo A/S. Gloucester acquires clinical-stage oncology drug
candidates and advances them through regulatory approval and commercialization.
The company's first candidate is in late-stage development for treatment of
T-cell lymphomas. Other investors in the company include Apple Tree Partners,
ProQuest Investments, Prospect Venture Partners and Rho Ventures.
http://www.gloucesterpharma.com

Jobs at Gloucester Pharma

Note:  At time of posting there were no jobs on their site.  But $29M can help with that!